Compare Quest Diagnostics Inc (DGX) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Otis Worldwide Corp — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Otis Worldwide Corp trades at $65.98 (market cap $25.17B). The key difference: Quest Diagnostics Inc and Otis Worldwide Corp are close in size by market cap, and Otis Worldwide Corp pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Otis Worldwide Corp for 66 Days on average.
| DGX | OTIS | |
|---|---|---|
Market Cap | $25.48B | $25.17B |
Volume | 941,866 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $247.45 | $93.62 |
52-Week Low | $173.49 | $64.05 |
Typical Hold Time | 56 Days | 66 Days |
Enterprise Value | $31.23B | $33.20B |
Dividend Yield | 1.49% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Otis Worldwide trades at $65.95, showing modest daily gains of 0.32% but remains near its 52-week low. The stock faces technical bearish signals with mixed fundamental performance - revenue growth remains stable at $14.43B (2025) but recent quarters show earnings misses. Analyst consensus is divided with 7 buy, 7 hold, and 1 sell ratings, while the company navigates margin pressures and China market challenges.
The outlook balances Otis's dominant market position and service-driven cash flows against margin pressures and weak equipment demand. With a $87 consensus price target suggesting 32% upside, the stock offers value but requires monitoring of service margin recovery and China exposure. Key risks include persistent cost inflation and execution challenges in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
